Features Testimonials Blog Assets

Try HeyTheo free

Home
Assets
MRNA — Moderna Inc

Get Deeper Analysis

Ask Theo anything about MRNA — earnings, valuation, technicals, or portfolio fit.

Try HeyTheo Free

Disclaimer: The information provided on this page is for informational purposes only and does not constitute financial advice, investment advice, or any other type of advice. HeyTheo does not recommend buying, selling, or holding any securities. Stock data is sourced from NASDAQ and SEC filings. AI-generated analysis is algorithmic and may contain errors. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance is not indicative of future results.

AI stock research, alerts and backtests

Explore

Company

About Disclosures Privacy Policy Terms & Conditions

Contact

support@heytheo.io

© 2026 HeyTheo. All rights reserved.

MRNANASDAQ— Moderna Inc Price & Analysis

Moderna Inc

HEALTHCARE — BIOTECHNOLOGY

$154.04

-$4.03-2.55%

Market Cap: $63.11B; Large Cap
P/E Ratio: N/A; Fwd: 23.04
EPS (TTM): $-8.66
Div. Yield: N/A

Technical Summary

RSI (14)63.26Neutral

SMA (50)$98.17Bullish

SMA (200)$60.25Bullish

MACD14.4899Bearish

Bollinger$132.60 – $159.19Mid

Stochastic73.71Neutral

Company Overview

Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.

Fundamental Snapshot

Revenue: $2.23B
EBITDA: $-2.19B
Gross Profit: $-1.47B
Operating Margin: -558.0%
Profit Margin: -141.4%
ROE: -39.0%
Book Value: $16.95
Beta: 1.11
52-Wk High: $176.66
52-Wk Low: $22.28
Avg Volume: 19.76M
PEG Ratio: 0

Trading Data

Open: $158.35
Previous Close: $158.07
Day Range: $150.26 – $159.79
Volume: 20.21M
Shares Outstanding: 399.24M
Analyst Target: $119.56

Related Assets

Gilead Sciences Inc

Intuitive Surgical Inc

Vertex Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc